Investing5d
Quoin seeks patent for skin disease treatment QRX003
ASHBURN, Va. - Quoin Pharmaceuticals Ltd. (NASDAQ: QNRX), a specialty pharmaceutical company with a market capitalization of $6.1 million, has filed a U.S. patent application for QRX003, a topical ...
Yahoo Finance5d
Quoin Pharmaceuticals Files U.S. Patent Application for Novel Topical Formulations to Treat Netherton Syndrome and Other Skin Diseases
ASHBURN, Va., March 25, 2025 (GLOBE NEWSWIRE) -- Quoin Pharmaceuticals Ltd. (NASDAQ: QNRX) (the “Company” or “Quoin”), a late-stage clinical, specialty ...
Nasdaq5d
Quoin Pharmaceuticals Files Patent Application for QRX003 to Treat Netherton Syndrome and Other Rare Skin Conditions
Quoin Pharmaceuticals Ltd. has filed a U.S. patent application for new topical formulations aimed at treating several skin diseases, specifically Netherton Syndrome (NS) and Peeling Skin Syndrome.
ETF Daily News11d
Q1 Earnings Estimate for QNRX Issued By Zacks Small Cap
Quoin Pharmaceuticals, Ltd. (NASDAQ:QNRX – Free Report) – Equities researchers at Zacks Small Cap issued their Q1 2025 EPS estimates for shares of Quoin Pharmaceuticals in a note issued to ...
Business Insider17d
Quoin Pharmaceuticals Provides Corporate Update and Reports Fourth Quarter and Full-Year 2024 Financial Results
ASHBURN, Va., March 13, 2025 (GLOBE NEWSWIRE) -- Quoin Pharmaceuticals Ltd. (NASDAQ: QNRX) (the "Company" or "Quoin"), a late clinical-stage specialty pharmaceutical company focused on rare and ...
Business Insider5d
Quoin Pharmaceuticals Files U.S. Patent Application for Novel Topical Formulations to Treat Netherton Syndrome and Other Skin Diseases
Target Indications Also Include Peeling Skin Syndrome, SAM Syndrome, Palmoplantar Keratoderma and Severe Atopic Dermatitis Third Quoin Patent Application for Netherton Syndrome If Granted Company ...